WuXi AppTec Co., Ltd. (WUXAY)

8.10

+0.41

+(5.33%)

At close: May 12 at 10:12:12 AM EDT

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first quarter ending March 31, 2025 ("Reporting Period"):

PR Newswire 15 days ago

WUXAY
+5.33%

WUXIF
WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstra

PR Newswire last month

WUXAY
+5.33%

WUXIF
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the year ending December 31, 2024 ("Reporting Period"):

PR Newswire last month

WUXAY
+5.33%

WUXIF
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, underscoring the company's enduring commitment to responsible business practices and supply chain resilience.

PR Newswire 3 months ago

WUXAY
+5.33%

WUXIF
WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been recognized by the prestigious Dow Jones Sustainability Indices (DJSI) for the fourth consecutive year. The company was included in both the 2024 DJSI World and the 2024 DJSI Emerging Markets, an achievement that acknowledges WuXi AppTec's ongoing commitment to sustainability and the integration of respons

PR Newswire 4 months ago

WUXAY
+5.33%

WUXIF
WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been awarded a gold medal in the 2024 EcoVadis business sustainability rating, ranking in the top 2% of all participating companies. This achievement reflects WuXi AppTec's commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the company's business st

PR Newswire 5 months ago

WUXAY
+5.33%

WUXIF
WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec's steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities i

PR Newswire 5 months ago

WUXAY
+5.33%

WUXIF
WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Global Corporate Sustainability Assessment (CSA), as of November 11, 2024.

PR Newswire 5 months ago

WUXAY
+5.33%

WUXIF
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a growth advisory firm. This marks the eighth consecutive year that WuXi AppTec has achieved this distinction.

PR Newswire 6 months ago

WUXAY
+5.33%

WUXIF
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first three quarters ending September 30, 2024 ("Reporting Period"):

PR Newswire 6 months ago

WUXAY
+5.33%

WUXIF
US bill to restrict business with China's WuXi AppTec, BGI passes House

(Reuters) -The U.S. House of Representatives passed a bill on Monday that aims to restrict business with China's WuXi AppTec, BGI and several other biotech companies on national security grounds, drawing condemnation from Beijing. The bill passed by 306 to 81, easily topping the two-thirds majority needed The legislation must pass the U.S. Senate before it can be sent to President Joe Biden to be signed into law.

Reuters 7 months ago

WUXAY
+5.33%
Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first half ending June 30, 2024 ("Reporting Period"):

PR Newswire 9 months ago

WUXAY
+5.33%

WUXIF

Performance Overview

Return	WUXAY	SSE Composite Index (000001.SS)
YTD	+14.08%	+0.69%
1-Year	+90.81%	+7.21%
3-Year	+90.81%	+9.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Breaking

WuXi AppTec Co., Ltd. (WUXAY)

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections

WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)

WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year

WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating

WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

US bill to restrict business with China's WuXi AppTec, BGI passes House

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

Performance Overview